From this selection, two DNAzymes, DNZ-15 and DNZ-35a, emerged as potent candidates, displaying robust cleavage activity in vitro and significant BCL-2 knockdown in liver carcinoma and breast cancer cells. This evidence concerns the gene BCL2 and hepatocellular carcinoma.